Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma

To evaluate the efficacy and safety of Xinlikang capsule in the treatment of cancer-related fatigue (CRF) and peripheral blood lymphocytes in patients with diffuse large B-cell lymphoma (DLBCL) who achieved complete remission (CR) after all courses of chemotherapy-containing regimens

Trial Details

NCT ID
NCT07084662
Phase
PHASE2 / PHASE3
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • Xinlikang capsules
  • mimic capsules
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Age ≥18 years old;
  • Newly diagnosed diffuse large B lymphoma (DLBCL);
  • Patients had completed the first-line treatment of chemotherapy and immunotherapy and the course of treatment had been completed.
  • Metabolic complete response (CR) was evaluated by PET/CT during or after chemotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →